Botox Competitor Jeuveau Launches A $49-A-Month Membership [Forbes]
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) [Yahoo! Finance]
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.